Nama Insights

Savara (SVRA)

Healthcare · Biotechnology · NASDAQ

Savara (SVRA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.15B and a free-cash-flow yield of -8.6%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.0/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Lagging · +0.0% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-39.1%
How far the last close sits under the highest price of the past five years.
Market cap$1.15B
Trailing P/E—
Price / book10.0
Price / sales—
FCF yield-8.6%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.3
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

SVRA earnings

Next report: Mar 12, 2027 (Q4 2026, EPS estimate -$0.17). Beat the EPS estimate in 0 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 9, 2026 -$0.17 -$0.17 +0.0% $0
Q2 2026 Aug 11, 2026 -$0.16 -$0.15 -6.7% $0
Q4 2025 Mar 13, 2026 -$0.13 -$0.12 -8.3% $0
Q3 2025 Nov 12, 2025 -$0.14 -$0.13 -7.7% $0

SVRA analyst price target

Median target $10.50 from 9 analysts, ranging $9.00 – $16.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live SVRA data on Nama Insights →

SVRA FAQ

Is SVRA a buy?
Nama's AI scorecard currently rates Savara Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SVRA report earnings?
Savara's next scheduled report is on Mar 12, 2027. Analysts expect EPS of -$0.17.
What is the SVRA price target?
The median analyst price target from 9 analysts is $10.50, with a range of $9.00 – $16.00.
Is SVRA Shariah compliant?
Nama's AAOIFI-style screen reads Savara as Can't Tell. A figure the screen needs is missing, so it can't tell.